Global Respiratory Syncytial Virus-Related Infant Community Deaths

dc.contributor.authorMazur, Natalie I
dc.contributor.authorLöwensteyn, Yvette N
dc.contributor.authorWillemsen, Joukje E
dc.contributor.authorGill, Christopher J
dc.contributor.authorForman, Leah
dc.contributor.authorMwananyanda, Lawrence M
dc.contributor.authorBlau, Dianna M
dc.date.accessioned2025-05-10T15:24:03Z
dc.date.issued2021
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractBackground: Respiratory syncytial virus (RSV) is a leading cause of pediatric death, with >99% of mortality occurring in low- and lower middle-income countries. At least half of RSV-related deaths are estimated to occur in the community, but clinical characteristics of this group of children remain poorly characterized. Methods: The RSV Global Online Mortality Database (RSV GOLD), a global registry of under-5 children who have died with RSV-related illness, describes clinical characteristics of children dying of RSV through global data sharing. RSV GOLD acts as a collaborative platform for global deaths, including community mortality studies described in this supplement. We aimed to compare the age distribution of infant deaths <6 months occurring in the community with in-hospital. Results: We studied 829 RSV-related deaths <1 year of age from 38 developing countries, including 166 community deaths from 12 countries. There were 629 deaths that occurred <6 months, of which 156 (25%) occurred in the community. Among infants who died before 6 months of age, median age at death in the community (1.5 months; IQR: 0.8-3.3) was lower than in-hospital (2.4 months; IQR: 1.5-4.0; P<.0001). The proportion of neonatal deaths was higher in the community (29%, 46/156) than in-hospital (12%, 57/473, P<0.0001). Conclusions: We observed that children in the community die at a younger age. We expect that maternal vaccination or immunoprophylaxis against RSV will have a larger impact on RSV-related mortality in the community than in-hospital. This case series of RSV-related community deaths, made possible through global data sharing, allowed us to assess the potential impact of future RSV vaccines. © 2021 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America.
dc.description.sponsorshipJohnson and Johnson, J&J; Merck; AbbVie; ; Roche; Astra Zeneca Inc; Bill and Melinda Gates Foundation, BMGF, (OPP1148988.8)
dc.identifier.doi10.1093/cid/ciab528
dc.identifier.endpageS237
dc.identifier.issn1058-4838
dc.identifier.pmid34472576
dc.identifier.scopus2-s2.0-85115279177
dc.identifier.scopusqualityQ1
dc.identifier.startpageS229
dc.identifier.urihttps://doi.org/10.1093/cid/ciab528
dc.identifier.urihttps://hdl.handle.net/20.500.14730/6619
dc.identifier.volume73
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherOxford University Press
dc.relation.ispartofClinical Infectious Diseases
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20250302
dc.subjectcommunity death; lower respiratory tract infection; respiratory syncytial virus
dc.titleGlobal Respiratory Syncytial Virus-Related Infant Community Deaths
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
6619.pdf
Boyut:
5.77 MB
Biçim:
Adobe Portable Document Format